new_analysis_nintedanib_SSc_ILD

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1  Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS ® trial, according to this analysis1

Source: Boehringer Ingelheim Corporate News - November 5, 2020 Category: Research Source Type: news